Novartis

Novartis Vaccines and Diagnostics: Novartis Begins Shipment to US of Fluvirin(R) Influenza Virus Vaccine With Three New Strains for the 2008-2009 Influenza Season

Market Wire - Pharmaceuticals and Biotech: Drugs (Free subscription) | 10 hours ago

CAMBRIDGE, MA (MARKET WIRE) Novartis announced today that it started shipments of its Fluvirin(R) Influenza Virus Vaccine to US health care facilities and practitioners for the 2008/2009 influenza season.

J.P. Morgan cuts Novartis to neutral

Market Watch (Free subscription) | yesterday

LONDON (MarketWatch) -- J.P. Morgan cut its rating on Swiss drugmaker Novartis to neutral from buy after a 14% share price rise since June. "In our view Novartis clearly deserves a premium to the sector due to better long-term growth prospects; however, we don't see fundamental or newsflow momentum that could result in further multiple expansion sufficient for further near-term sector outperformance,"...

Protests at Novartis in Dublin Continue

Indymedia ireland (Free subscription) | yesterday

Stop Huntingdon Animal Cruelty (SHAC) For the past few weeks we've been having regular demonstrations outside Novartis in Dublin (Regus House, Harcourt Road, Dublin 2).

Emisphere Announces Recruitment Of Novartis Phase III Study For Oral Osteoporosis Treatment

Medical News Today (Free subscription) | yesterday

Emisphere Technologies, Inc. (Nasdaq: EMIS) announced that Novartis Pharma AG has finished recruitment for a multi-center Phase III study exploring the safety and efficacy of Salmon Calcitonin and Emisphere's proprietary Eligen(R) Technology in the treatment of vertebral fractures in postmenopausal women aged 60-80 with osteoporosis.

• Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment - PR News Wire

Novartis simplifies Rx access and management programs in USA

Inbox Robot: Swiss Reinsurance News (Free subscription) | 08/05/2008

Novartis simplifies Rx access and management programs in USA New Jersey, USA-based Novartis Pharmaceuticals Corp, a unit of the Swiss drug major has launched ...

FDA Approves Novartis's Combination Medications for Blood Pressure Treatment

Red Orbit (Free subscription) | 08/05/2008

Novartis Pharmaceuticals has announced that the FDA has approved two single-pill combination medications, Diovan HCT and Exforge, as initial or 'first-line' therapies in patients likely to need multiple drugs to achieve their blood pressure goals.

• Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure - The Earth Times Online Newspaper
• Single-Pill Combinations Diovan HCT And Exforge Approved In US As First-Line Treatments For High Blood Pressure - Medical News Today
• See the 5 articles on the same subject

Research and Markets: Novartis Partnering Guide 2008: An In-depth Insight into the Partnering Interests and Activities of one of the World's Leading Biopharma Companies

Business Wire (Free subscription) | 08/05/2008

One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Diovan HCT and Exforge approved as first-line therapies in USA

Inbox Robot: Swiss Reinsurance News (Free subscription) | 08/05/2008

Diovan HCT and Exforge approved as first-line therapies in USA Novartis has received a major boost in the USA after regulators there gave their ...

Bayer sues Novartis over birth-control pill

Denver Post (Free subscription) | 08/05/2008

Bayer sued Novartis' Sandoz unit to prevent it from selling a copy of the Yaz birth-control pill in the U.S.

SPEEDEL BOARD OF DIRECTORS RECOMMENDS SHAREHOLDERS TO ACCEPT ANNOUNCED NOVARTIS OFFER

The Earth Times Online Newspaper (Free subscription) | 08/05/2008

BASEL, SWITZERLAND -- 08/05/08 -- Speedel Holding Ltd. (SWX: SPPN) today announced the recommendation of the Board of Directors regarding the public tender offer pre-announced by Novartis on 10 July 2008. The Board of Directors ..

U.S. approves two Novartis blood pressure pills

Health - The Post Chronicle (Free subscription) | 08/04/2008

U.S. regulators have approved two single-pill high blood pressure drugs......

• Novartis: FDA OKs Diovan HCT, Exforge for first-line use - Market Watch
• Single-Pill Combinations Diovan HCT and Exforge Approved in US as First-Line Treatments for High Blood Pressure - The Earth Times Online Newspaper
• See the 4 articles on the same subject

Oh come off it...

The Croydonian (Free subscription) | 08/04/2008

Today's scarcely credible research finding comes from the Partnership for a Drug Free America ( Doubtless Pfizer, Glaxo, Novartis etc are a little concerned as to what a DFA would do to their business models, but less of that later ), which polled teenagers for its 2007 ( a bit late, people ) Partnership Attitude Tracking Study. And what is the number one (73%) response to the question, ' why do kids...

KV Pharmaceutical's Motion for Rule 11 Sanctions in Ritalin LA Case Denied

Seeking Alpha (Free subscription) | 08/04/2008

Aaron F. Barkoff submits: Celgene and Novartis v. KV Pharm. , No. 07-4819 (D.N.J. 2008) KV Pharmaceutical (KVA) filed an ANDA for a generic version of Ritalin LA (methylphenidate HCl extended-release capsules) with paragraph IV certifications to Celgene's (CELG) U.S. Patent Nos. 5,837,284 and 6,635,284 . Apparently KV made an offer of confidential access to its ANDA, but Celgene and Novartis (NVS)...

• District Court Denies Early Motion For Rule 11 Sanctions in Ritalin LA Case - Orange Book Blog

U.S. approves two Novartis blood pressure pills

OTB News (Free subscription) | 08/04/2008

ZURICH (Reuters) - U.S. regulators have approved two single-pill high blood pressure drugs, Diovan HCT and Exforge, from Switzerland’s Novartis AG, the drugmaker said on Monday.

U.S. approves two Novartis blood pressure pills

Reuters UK (Free subscription) | 08/04/2008

ZURICH (Reuters) - U.S. regulators have approved two single-pill high blood pressure drugs, Diovan HCT and Exforge, from Switzerland's Novartis AG, the drugmaker said on Monday.

AMD Market Outlook to 2012

nitesh | 12/18/2007

AMD is the most common cause of vision loss in the developed world for those over 50 years of age. We estimate there are over 20 million cases in the US and Europe. Dry AMD accounts for 90% of cases and has no suitable cure. Wet AMD drug sales will soon see the first blockbuster. Novartis achieved first to market success with their Visudyne drug in 1999. However work from Pfizer selling Macugen and...

Novartis Market Outlook, Forecasts and Analysis to 2012

nitesh | 12/18/2007

With headquarters in Basel, Switzerland, Novartis is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, high revenue growth, acquisitions, breadth of portfolio, product launches and pipeline developments. In 2006 - ten years after its inception - Novartis generated total net sales of $37bn worldwide. Novartis Market Outlook 2012 Report, examines the Novartis...